华蟾素治疗慢性乙型肝炎病毒携带者临床研究

Clinical Study on Cinobufotalin in Treating Chronic Hepatitis B Virus Carriers

采用华蟾素治疗慢性乙型肝炎病毒(HBV)携带者147例,每日肌肉注射4ml,30天为1疗程,用药1～3个疗程。结果治疗组HBsAg、HBeAg、PHSA-R、DNAP阴转率分别为21.09%、38.89%、63.64%、50%,明显高于对照组(143例,以维丙肝、山豆根或甘草甜素治疗)的2.1%、10.87%、33.33%及7.7%(P<0.001～0.02)。抗-HBS、抗-HBe的阳转率前者为19.29%及23.45%,亦明显高于后者的4.26%及7.14%(P<0.001)。表明华蟾素对HBV复制有较明显的抑制作用。

In a preliminary study, carriers of hepatitis B virus were treated with Cinobufotalin, a prepara- tion from toad, for 1-3 course of treatment. Results indicated that negative conversion rate was markedly higher in the treated groups (21.09%, 38.89%, 63.64% and 50%) than that of control groups (2.1%, 10.87%, 33.33% and 7.7% P<0.001). By the end of treatment, positive conversion rate of anti- HBs and anti-HBe were also markedly higher in the former (19.29% and 23.45%) than that in the latter (4.26% and 7.14% P<0.001). During the follow-up of 3-6 months, the positive rate of HBeAg in treated group (50%) raised as compared with the control group (20% P=0.08). The results indicated that Cinobufotalin had a significant effect in inhibiting the replication of HBV.